Last reviewed · How we verify
Profenol (SUPROFEN)
Profenol, also known as Suprofen, is a small molecule drug developed by Alcon that targets Prostaglandin G/H synthase 1. It was approved by the FDA in 1988 for certain indications, but its exact indications are not specified in the provided facts. As an off-patent drug with no active Orange Book patents, Suprofen is available as a branded product owned by Alcon, with no generic manufacturers. The drug has a half-life of 2.1 hours and a bioavailability of 92%. Key safety considerations are not specified in the provided facts.
At a glance
| Generic name | SUPROFEN |
|---|---|
| Sponsor | Novartis |
| Drug class | suprofen |
| Target | Cytochrome P450 2C9, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1988 |
Approved indications
Common side effects
- Burning and stinging
- Discomfort
- Itching
- Redness
Serious adverse events
- Allergy
- Iritis
- Pain
- Chemosis
- Photophobia
- Irritation
- Punctate epithelial staining
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Profenol CI brief — competitive landscape report
- Profenol updates RSS · CI watch RSS
- Novartis portfolio CI